Jonathan R Matias

age ~68

from Cold Spring, NY

Get Report

Also known as:

Connected to:

Jonathan Matias Phones & Addresses

Non-Toxic Coating Composition, Methods Of Use Thereof And Articles Protected From Attachment Of Biofouling Organisms
view source
US Patent:

20020022044, Feb 21, 2002
Filed:

Jun 8, 2001
Appl. No.:

09/878029
Inventors:

Jonathan Matias - New York NY, US
International Classification:

A01N025/00
US Classification:

424/405000
Abstract:

Antifouling coating compositions and methods are disclosed, in which the active agent is preferably (-)trans-p-menthane-3,8-diol, (-)-menthol, (-)-menthyl chloride, menthoxypropanediol, (-)-isopulegol or (-)-menthone.

Menthol Propyleneglycol-Carbonate And Analogs Thereof As Insect Pest Repellents
view source
US Patent:

20060270737, Nov 30, 2006
Filed:

Aug 18, 2004
Appl. No.:

10/595143
Inventors:

Jonathan Matias - Hollis NY, US
International Classification:

A01N 37/02
A01N 37/18
US Classification:

514546000, 514613000
Abstract:

Menthol propyleneglycol-carbonate, analogs thereof and compositions containing such compounds are useful as insect repellents.

Non-Toxic Coating Composition, Methods Of Use Thereof And Articles Protected From Attachment Of Biofouling Organisms
view source
US Patent:

20080095737, Apr 24, 2008
Filed:

Dec 17, 2007
Appl. No.:

11/957907
Inventors:

JONATHAN MATIAS - Hollis NY, US
Assignee:

Symrise GmbH & Co. KG - Holzminden
International Classification:

A01N 31/14
A01P 15/00
US Classification:

424078090
Abstract:

Antifouling coating compositions and methods are disclosed, in which the active agent is preferably (−)trans-p-menthane-3,8-diol, (−)-menthol, (−)-menthyl chloride, menthoxypropanediol, (−)-isopulegol or (−)-menthone.

Methods Of Using Menthol Propyleneglycol-Carbonate And Analogs Thereof For Producing Anti-Inflammatory And Anti-Angiogenic Effects
view source
US Patent:

20090203776, Aug 13, 2009
Filed:

Sep 23, 2005
Appl. No.:

11/575888
Inventors:

Jonathan R. Matias - Hollis NY, US
International Classification:

A61K 31/265
A61K 31/047
A61P 29/00
US Classification:

514512, 514738
Abstract:

Menthol propyleneglycal-carbonate, analogs thereof and compositions containing such compounds are administered to mammals, preferably humans, to produce anti-inflammatory or anti-angiogenic effects.

Methods For Treatment Of Male-Pattern Baldness
view source
US Patent:

50534033, Oct 1, 1991
Filed:

Nov 20, 1989
Appl. No.:

7/438979
Inventors:

Norman Orentreich - New York NY
Jonathan R. Matias - Richmond Hill NY
International Classification:

A61K 3156
US Classification:

514170
Abstract:

Synergistic compositions for inhibiting the action of androgens comprise the combination in a single topical preparation of a 5. alpha. -reductase enzyme inhibitor and an androgen receptor blocking agent in a pharmaceutically and dermatologically acceptable vehicle. The compositions may be topically applied to affected areas of the skin in the treatment or prevention of sebaceous gland hypertrophy, hirsutism and male-pattern baldness in mammals. The inhibitor and blocking agent are present in the composition in a weight ratio of about 1:20 to 5:1, with the inhibitor comprising up to about 0. 1% w/v of the comopsition and the blocking agent comprising up to about 1% w/v of the composition.

Compositions And Methods For Inhibiting The Action Of Androgens
view source
US Patent:

46846352, Aug 4, 1987
Filed:

Mar 27, 1986
Appl. No.:

6/846498
Inventors:

Norman Orentreich - New York NY
Jonathan R. Matias - Richmond Hill NY
International Classification:

A61K 3156
US Classification:

514170
Abstract:

Synergistic compositions for inhibiting the action of androgens comprise the combination in a single topical preparation of a 5. alpha. -reductase enzyme inhibitor and an androgen receptor blocking agent in a pharmaceutically and dermatologically acceptable vehicle. The compositions may be topically applied to affected areas of the skin in the treatment or prevention of sebaceous gland hypertrophy, hirsutism and male-pattern baldness in mammals. The inhibitor and blocking agent are present in the composition in a weight ratio of about 1:20 to 5:1, with the inhibitor comprising up to about 0. 1% w/v of the composition and the blocking agent comprising up to about 1% w/v of the composition.